Emergence of Candida auris in intensive care units in Algeria

Mycoses. 2022 Jul;65(7):753-759. doi: 10.1111/myc.13470. Epub 2022 May 31.

Abstract

Background: Currently, Candida auris is among the most serious emerging pathogens that can be associated with nosocomial infections and outbreaks in intensive care units. Clinicians must be able to identify and manage it quickly.

Objective: Here, we report for the first time in Algeria seven cases of C. auris infection or colonisation.

Methods and results: The strains were isolated from clinical sites including bronchial aspirates (n = 4), wound swabs (n = 1), urine sample (n = 1) and peritoneal fluid (n = 1), in patients admitted to the intensive care unit. Candida auris was identified both by MALDI-TOF and by sequencing the ITS region and the D1/D2 domain. Antifungal susceptibility testing was performed using the E-test method. Non-wildtype susceptibility was observed for five strains against fluconazole, itraconazole, voriconazole and caspofungin. Genotyping showed the presence of four clades (I-IV) in one hospital.

Conclusions: Appropriate antifungal treatments with rapid and accurate microbial identification are the cornerstone for the management and control of C. auris infections.

Keywords: Candida auris; Algeria; ICU; clades (I-IV); emergence.

MeSH terms

  • Algeria / epidemiology
  • Antifungal Agents* / pharmacology
  • Antifungal Agents* / therapeutic use
  • Candida / genetics
  • Candida auris
  • Candidiasis* / diagnosis
  • Candidiasis* / drug therapy
  • Candidiasis* / epidemiology
  • Humans
  • Intensive Care Units
  • Microbial Sensitivity Tests

Substances

  • Antifungal Agents